ReviewFrontiers in neurology2026
NETs and the thrombo-immune microenvironment: immune heterogeneity in recanalization, reperfusion, hemorrhagic transformation, and antithrombotic strategies.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reperfusion therapies have revolutionized the treatment of acute ischemic stroke (AIS), but target-artery recanalization, downstream angiographic reperfusion, microvascular tissue reperfusion, and functional recovery are distinct endpoints. Patients may have persistent occlusion or early reocclusion, incomplete modified Thrombolysis in Cerebral Infarction (mTICI) reperfusion, microvascular no-reflow despite high-grade mTICI/eTICI reperfusion, hemorrhagic transformation (HT), or poor 90-day functional outcome. Neutrophil extracellular traps (NETs) form a mechanistic link between thrombus structure, innate immune activation, endothelial injury, and antithrombotic responses. NETs provide a DNA-histone scaffold that stabilizes fibrin-rich thrombi, recruits platelets and coagulation factors, and exposes the neurovascular unit to cytotoxic granular proteins. The biological characteristics of NETs nevertheless vary among patients. Differences in neutrophil priming, platelet activation, monocyte-endothelial signaling, thrombus composition, collateral status, concurrent inflammation, and reperfusion injury create distinct thrombo-immune microenvironments. This article reviews how NET-driven immunothrombosis affects arterial recanalization, angiographic and tissue reperfusion, HT, and emerging antithrombotic strategies. It also proposes an operational immune-phenotyping framework with candidate biomarkers, assay-dependent research thresholds, sampling time points, and trial-level decision rules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.